Stock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects

Stock Track

02-21

GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.

Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.

Additionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1144662197"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144662197\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1144662197?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-21 17:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144662197","market":"hk","top_or_hot":-1,"title":"Stock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects","media":"Stock Track","content":"<p>GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.</p>\n\n<p>Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.</p>\n\n<p>Additionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-21 17:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.</p>\n\n<p>Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.</p>\n\n<p>Additionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRAL","symbol_name":"GRAIL, Inc.","start_time":0,"source_url":"","article_id":"1144662197","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144662197","pubTimestamp":1740130351,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GRAIL, Inc.  saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRAL":"GRAIL, Inc."},"translate_title":"由于癌症筛查和机器人出租车前景乐观，GRAIL，Inc.盘前飙升7.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":1},"content_text":"GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.\nAnalysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.\nAdditionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}